Unitree’s $618 Million IPO Approval: What the STAR Market Listing Means
Unitree Robotics has cleared the regulatory stage for a Shanghai STAR Market IPO that is expected to raise approximately $618 million. The China Securities Regulatory Commission approved the company’s registration application in a notice dated July 1, 2026, after reviewing the Shanghai Stock Exchange’s opinion and Unitree’s registration documents. The approval is valid for 12 months, but it does not itself set a listing date, offer price or final market capitalization. The CSRC registration notice confirms the approval and the conditions attached to it.
The proposed transaction would value Unitree at roughly $5.9 billion to $6 billion, based on reported estimates around a 40 billion yuan valuation. That figure remains an indication rather than a completed market price: the final valuation will depend on the offering structure, bookbuilding and the price at which the shares begin trading. A reported estimate from a Unitree investor placed the potential valuation near 40 billion yuan.
What Unitree’s approval actually changes
The approval removes the most important regulatory hurdle, but it is not the same as a completed IPO. Unitree must still finalize the offering documents, underwriting arrangements, pricing and subscription process before shares can begin trading. Reuters reported on July 3 that the company had not yet announced a launch date or price range. The Reuters report carried by MarketScreener also said the approval would remain valid for 12 months.
For readers following the robotics sector, the practical meaning is that Unitree is moving from a private-company valuation story toward a public-market price discovery process. Until the shares are priced and trading begins, the approximately $6 billion figure should be treated as a target or implied valuation, not as a live market capitalization.
Why the review attracted attention
Unitree’s application was formally accepted by the Shanghai Stock Exchange on March 20, 2026, and the exchange’s listing committee reviewed it on June 1. Caixin reported that the process took 73 days from acceptance to registration clearance, beating the previous 88-day record for a STAR Market IPO. Caixin’s account of the accelerated review linked the speed to China’s effort to direct capital toward strategic technology sectors such as artificial intelligence, robotics and semiconductors.
The Shanghai Stock Exchange had already described the June committee decision as one of the fastest IPO reviews in China that year. Its announcement said Unitree had passed the Listing Committee review, clearing a major step toward becoming one of the first publicly traded humanoid robotics companies in China. The exchange’s own announcement confirms the committee review, although it does not establish a completed listing or final valuation.
The 73-day figure is therefore best understood as a regulatory-process milestone. It does not demonstrate that Unitree has solved the commercial questions facing humanoid robotics, including repeat demand, deployment economics, service costs and long-term margins.
How much money Unitree plans to raise
The prospectus plan calls for Unitree to raise about 4.2 billion yuan, equivalent to roughly $616 million to $619 million depending on the exchange rate used. The reported dollar figure of $618 million is a rounded description of the same fundraising target. Xinhua, citing the company’s prospectus, reported that the proceeds would support intelligent robot model research, robotic-body research, new product development and construction of an intelligent robot manufacturing base. The Xinhua report summarizes the disclosed use of proceeds.
Reuters reported that Unitree planned to sell at least 40.45 million new shares. The company had not disclosed a final price range at the time of that report, so the amount raised and the implied valuation should not be confused with guaranteed proceeds after pricing adjustments or changes to the offering plan.
For Unitree, the allocation matters more than the headline amount. Spending on models, robot bodies and production capacity indicates an attempt to fund the full hardware-and-software stack rather than only expand sales of existing machines. The investment case will depend on whether that capital produces higher volumes, better reliability and repeatable customer deployments.
What Unitree’s business profile tells investors
Unitree is based in Hangzhou and develops humanoid robots, quadruped robots, robot components and embodied artificial-intelligence models. Xinhua described the company as one of the early commercializers of high-performance quadruped robots for industrial scenarios, while the IPO plan places increasing emphasis on humanoid robotics and related AI systems.
The disclosed financial trajectory shows rapid growth. According to the prospectus figures reported by Xinhua, operating revenue increased from 159 million yuan in 2023 to 393 million yuan in 2024 and nearly 1.7 billion yuan in 2025. The company expected first-half 2026 revenue between 1.052 billion yuan and 1.128 billion yuan, with adjusted net profit attributable to the parent company projected between 236 million yuan and 283 million yuan. Those are company or prospectus figures, not independent forecasts.
That growth profile helps explain the market’s interest, but it also creates a demanding valuation test. A company approaching a $6 billion implied valuation must persuade public investors that recent expansion reflects durable demand rather than a temporary surge in attention, promotional orders or early-stage industry spending.
Why the valuation is difficult to read
The proposed valuation is a reference point for the sector, not a verdict on the economics of humanoid robots. Caixin previously reported that Unitree was seeking a valuation of approximately 42 billion yuan, or about $6.2 billion, while later coverage placed the expected figure closer to $5.9 billion. The earlier valuation report shows why the number should be read as an evolving offering target.
Investors should separate three variables:
- Fundraising size: how much new capital Unitree intends to obtain.
- Post-money valuation: the company’s implied value after the new shares are priced.
- Trading performance: the price public investors are willing to pay after the listing.
A strong first session could produce a higher market value, while weak demand could force a lower price or delay the transaction. Neither outcome can be inferred from the CSRC approval alone.
The commercial question behind the IPO
The central question is not whether Unitree can manufacture visible robots. It is whether customers will pay for systems that perform useful work reliably enough to justify deployment, maintenance and integration costs.
Associated Press reported that China had more than 140 humanoid robot manufacturers and more than 330 models in 2025, while also noting that many machines remained performative or limited in practical applications. The same report said a substantial share of Chinese humanoid-robot orders came from state-owned enterprises and were used in areas such as power plants, data centers and entertainment. AP’s reporting on demand and deployment constraints is useful context for evaluating the sector beyond product demonstrations.
This distinction matters because early deployments can validate engineering and supply-chain capability without proving broad commercial demand. A practical investor checklist should therefore ask whether disclosed customers are buying repeat units, whether robots are generating measurable operating savings and whether revenue depends on a narrow group of government-linked or promotional projects.
What the STAR Market route signals
The STAR Market was created for high-technology and strategic emerging companies, making it a natural venue for a robotics business that combines hardware, AI models and manufacturing. Xinhua noted that the market was launched at the Shanghai Stock Exchange in 2019 to support high-tech companies and that Unitree was the second company to file under a pilot pre-review mechanism introduced in 2025.
The fast review is also a policy signal. Caixin reported that the average wait for STAR Market IPOs fell to less than six months in 2025 from roughly a year in 2023 and 2024, while Unitree’s 73-day process was faster still. That suggests regulators are willing to accelerate selected technology listings, but it does not mean every robotics issuer will receive the same timetable or treatment.
For the broader market, Unitree could become a public reference point for privately held robotics companies considering their own listings. Its share price may influence how investors assess competitors, suppliers and funds with exposure to embodied AI. That influence will be strongest if Unitree provides clear operating disclosures after listing rather than relying primarily on demonstrations and sector narratives.
What investors should monitor before the debut
Anyone tracking the IPO should wait for the final offering documents and focus on information that can be checked directly.
- Confirm the final share count, price range, expected proceeds and post-offering ownership structure.
- Compare humanoid-robot revenue with quadruped, component and other product revenue.
- Read the risk disclosures on customer concentration, inventory, warranty obligations, supply chains and research spending.
- Check whether the manufacturing-base investment is tied to signed demand or reflects expected future demand.
- Review the first quarterly reports after listing before treating the IPO valuation as validated.
The most common error would be to treat regulatory speed as proof of technological leadership or to treat the valuation estimate as an investable price. A second mistake would be to compare Unitree only with software companies; its economics will also be shaped by factory utilization, component costs, repairs, logistics and working capital.
What the approval means as of July 21, 2026
As of July 21, Unitree has regulatory clearance for the IPO but has not yet provided a confirmed launch date or final price range in the sources reviewed. Market commentary has focused on a possible late-July debut, yet the reliable operational milestone is still the CSRC registration approval, not a completed listing.
The next useful update will be the formal offering schedule. Until then, the disciplined interpretation is straightforward: Unitree has secured access to public-market financing at an indicated valuation near $6 billion, and the transaction will test whether investor enthusiasm for humanoid robotics can withstand detailed disclosure, pricing discipline and evidence of repeatable commercial demand.
The practical takeaway
Unitree’s approval is significant because it turns a major humanoid-robotics company into a near-term public-market candidate and could establish a valuation benchmark for China’s robotics sector. It is not, by itself, proof that humanoid robots are ready for mass deployment or that the proposed valuation will survive public trading.
For now, the sensible next step is to follow the final prospectus, pricing announcement and first post-listing financial disclosures. Those documents will show whether the $618 million raise is funding a scalable robotics business or mainly financing an expensive race to industrialize an emerging category.
Also read:
Subscribe to our newsletter
Get the latest Web3, AI, and crypto news delivered straight to your inbox.